Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;107(1):207-12.
doi: 10.1007/s11060-011-0738-7. Epub 2011 Oct 9.

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Matthew Koshy  1 , John L Villano, Therese A Dolecek, Andrew Howard, Usama Mahmood, Steven J Chmura, Ralph R Weichselbaum, Bridget J McCarthy
Affiliations

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Matthew Koshy et al. J Neurooncol. 2012 Mar.

Abstract

The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P < 0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest No author indicated a conflict of interest.

Figures

Fig. 1
Fig. 1
Overall relative survival of cohort stratified by diagnosis year groups
Fig. 2
Fig. 2
Overlay of Kaplan–Meier survival curves of patients with glioblastoma diagnosed from 2005–2006 from the SEER Registry and patients enrolled on the EORTC/NCIC trial treated with postoperative radiation and temozolomide
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. 2010;17:417–421. - PubMed
    1. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10–14. - PubMed
    1. Curran WJ, Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710. - PubMed
    1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123. - PubMed
    1. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. 2010

Publication types

MeSH terms